Petit Institute Seminar

Event Details
  • Date/Time:
    • Thursday May 26, 2016
      11:00 am - 12:00 pm
  • Location: Parker H. Petit Institute for Bioengineering and Bioscience, Room 1128
  • Phone: (404) 894-6228
  • URL: http://petitinstitute.gatech.edu/
  • Email:
  • Fee(s):
    N/A
  • Extras:
Contact

Bob Guldberg, Ph.D. - faculty host

Summaries

Summary Sentence: "Blood, Biomechanics and the Fountain of Youth - Fundamental Orthopaedic Trauma Biology" - Jonathan G. Schoenecker, M.D., Ph.D. - Vanderbilt University School of Medicine

Full Summary: No summary paragraph submitted.

Media
  • Parker H. Petit Institute for Bioengineering & Bioscience Parker H. Petit Institute for Bioengineering & Bioscience
    (image/jpeg)

"Blood, Biomechanics and the Fountain of Youth - Fundamental Orthopaedic Trauma Biology"

Jonathan G. Schoenecker, M.D., Ph.D.

Assistant Professor
Department of Orthopaedics, Pharmacology, and Pediatrics
Vanderbilt University School of Medicine

Abstract
Bone requires a rich vascular supply. Upon fracture this vascular supply is compromised in addition to the structural integrity of bone. Vascular regeneration requires periosteum, immediately precedes and is essential for restoration of the biomechanical integrity of bone. Understanding revascularization and biomechanical principles of fracture repair is essential for choosing proper types and duration of immobilization or implant devices. The mechanisms by which fractures revascularize will be discussed and how devices used to stabilize fractures affect these mechanisms.  

The BlueJeans link for the seminar is https://bluejeans.com/522643089

Research
My research laboratory is dedicated to define the integrated role of coagulation and inflammation on orthopaedic related wound healing. My unique focus stems from my surgical training in musculoskeletal diseases in combination with my basic science training in coagulation and bone biology.

Our initial experiments have employed models of bone growth, tumor and wound healing to characterize and manipulate cell membrane associated coagulation receptors including tissue factor, thrombomodulin and protease activated receptors. Utilizing these same models, we are investigating how the currently used coagulation associated orthobiologics affect bone growth. Over the next 5-10 years I propose to develop novel coagulation based pharmaceuticals capable of manipulating fracture healing in osteoporotic bone or inhibiting bone based tumors and infections.

Clinically, we are developing new measures of coagulation to quantify hypercoaguability. Current clinical tests of coagulation are incapable of quantifying hypercoaguability. Instead, it can only be measured through surrogate markers such as the development of a DVT. These markers represent the end-stage complications of hypercoaguability and are impractical measures. Furthermore, because the extent and duration of orthopaedic and surgically related hypercoaguability has not been reported, it is unknown how long treatment of hypercoaguable plasma with anticoagulation is required. As a result, patients are treated in the post-surgical period with a a??standarda?? dose of anticoagulant due to the absence of methods to inform accurate dosing or duration of therapy. This approach places patients at serious risk for developing complications either from i) under-treatment leaving the patient unprotected from hypercoaguability or ii) over-treatment, putting the patient at risk for hemorrhage, hematoma and complications of traumatic and surgical wound healing. Our preliminary data suggest that thrombin generation assays enable the sensitive detection orthopaedic and surgically related hypercoaguability. Therefore, clinically I propose that utilization of this assay will provide rational dose regiments for anticoagulant therapy for these patients. These studies have been initiated and will likely encompass the next 10 years of my clinical research program. Further, recent evidence suggests that many diseases treated by pediatric orthopaedic surgeons are secondary to a hypercoaguable state, such as; Legg-Calves-Perthes disease, osteosarcoma, osteomyelitis and cerebral palsy. We hope over the next five years to apply our novel clinical test to these diseases with the goal of diagnosing and treating the coagulation aspects of these diseases.

The strength of this research program is its uniqueness and clinical relevance. Coagulation research and its pharmaceutical application have already been identified by major cross-disciplinary clinical and research organizations for subject directed funding. The major innovation of this research is that it will i) provide a quantitative measure of hypercoaguability and ii) determine the critical threshold of hypercoaguability that is required for optimal skin and bone wound healing. These studies will have direct and immediate implications for patients undergoing orthopaedic surgery by defining optimal treatment strategies that prevent the complications of the hypercoaguable state, but permit wound healing. They will also allow potentially provide a novel understanding of the pathophysiology of many common diseases specific to pediatric orthopaedics.

Related Links

Additional Information

In Campus Calendar
Yes
Groups

Parker H. Petit Institute for Bioengineering and Bioscience (IBB)

Invited Audience
Undergraduate students, Faculty/Staff, Graduate students
Categories
Seminar/Lecture/Colloquium
Keywords
IBB
Status
  • Created By: Colly Mitchell
  • Workflow Status: Published
  • Created On: Apr 28, 2016 - 7:47am
  • Last Updated: Apr 13, 2017 - 5:15pm